B-Type Natriuretic Peptide And Vasopeptidase Activity In Children With Congenital Heart Diseases

Abstract

Background: This study aimed to compare the serum concentration of B-type natriuretic peptide (BNP) with vasopeptidase in CHD. In addition, to verify the diagnostic value of its concentration in congenital heart disease, as well as to verify the diagnostic value of BNP inhibition by vasopeptidase in congenital heart disease.

Method: cross sectional study included 80 patients:40 patients with congenital heart disease and 40 healthy subjects during the period from 1 March 2021 to 30 June 2021. Enzyme-linked immunosorbent assay (ELISA) kits determined the B-type natriuretic peptide (BNP) enzyme and vasopeptidase inhibitor (VPI).

 Results: This study demonstrated a significant association between B-type natriuretic peptide (BNP) and disease progression and severity in patients with congenital heart diseases. The study also showed significantly higher levels of “B-type natriuretic peptide BNP” enzymes in patients have severe symptoms and a lower level of vasopeptidase.

Conclusion: Examine the health BNP act as risk factor related to CHD that related with predisposition genes, so that it give an origin for the clinical recognition of CHD.